Cutaneous reactions with enfortumab vedotin: A case series and review of the literature

Allison S Dobry,Cesar Antonio Virgen,Anna-Marie Hosking,Nataliya Mar,Linda Doan,Bonnie Lee,Janellen Smith

doi:10.1016/j.jdcr.2021.05.020

Allison S Dobry, Cesar Antonio Virgen + Show 5 more

Open Access

https://doi.org/10.1016/j.jdcr.2021.05.020

Copy DOI

Abstract

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature

Highlights

Enfortumab vedotin (EV) is a novel treatment for patients with advanced urothelial carcinoma who have failed platinum-based chemotherapy and immunotherapy.[1]
Histopathology revealed subtle interface dermatitis accompanied by a perivascular lymphocytic infiltrate with eosinophils and neutrophils, marked dyskeratosis, and epidermal dysmaturation (Fig 2, A)
The rash improved with clobetasol ointment, 16 days after EV infusion, he was transferred to the medical intensive care unit for vasodilatory shock concerning hypersensitivity reaction and received prednisone

Summary

CASE SERIES

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature. MD,a Cesar Antonio Virgen, MD, PhD,b Anna-Marie Hosking, MD,a Nataliya Mar, MD,c Linda Doan, MD, PhD,a Bonnie Lee, MD,a and Janellen Smith, MDa Irvine, California and Boston, Massachusetts

INTRODUCTION

Findings

DISCUSSION